ESC 365 - Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

Open Access

Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

Session: Advances in cardiovascular pharmacotherapy

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor A. Mohamed (Copenhagen, DK)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Abdullahi Ahmed Mohamed

Herlev and Gentofte Hospital, Copenhagen (Denmark)

0 follower

5 more presentations in this session

Intravenous loop diuretic-induced decongestion in heart failure: an explorative study in a real-world population

Speaker: Mr M. Erhardsson (Stockholm, SE)

Efficacy and safety of sotagliflozin in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy (SONATA-HCM): study design

Speaker: Professor I. Olivotto (Florence, IT)

The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes

Speaker: Doctor A. Esteban Fernandez (Leganes, ES)

Assessing the best anticoagulation strategy for left ventricle thrombus after anterior myocardial infarction

Speaker: Doctor F. Rodrigues Santos (Viseu, PT)

Direct oral anticoagulants in patients with heart failure and atrial fibrillation: do we have an ideal score to predict major bleeding?

Speaker: Doctor V. De Simone (Legnago, IT)

Access the full session

Advances in cardiovascular pharmacotherapy

Speakers: Doctor A. Mohamed, Mr M. Erhardsson, Professor I. Olivotto, Doctor A. Esteban Fernandez, Doctor F. Rodrigues Santos...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources